{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T21:56:27Z","timestamp":1786830987431,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The success of chimeric antigen receptor (CAR) T cells in treating B cell malignancies comes at the price of eradicating normal B cells. Even though T cell malignancies are aggressive and treatment options are limited, similar strategies for T cell malignancies are constrained by the severe immune suppression arising from bystander T cell aplasia. Here, we show the selective killing of malignant T cells without affecting normal T cell-mediated immune responses in vitro and in a mouse model of disseminated leukemia. Further, we develop a CAR construct that carries the single chain variable fragment of a subtype-specific antibody against the variable TCR \u03b2-chain region. We demonstrate that these anti-V\u03b28 CAR-T cells are able to recognize and kill all V\u03b28<jats:sup>+<\/jats:sup>malignant T cells that arise from clonal expansion while sparing malignant or healthy V\u03b28<jats:sup>\u2212<\/jats:sup>T cells, allowing sufficient T cell-mediated cellular immunity. In summary, we present a proof of concept for a selective CAR-T cell therapy to eradicate T cell malignancies while maintaining functional adaptive immunity, which opens the possibility for clinical development.<\/jats:p>","DOI":"10.1038\/s41467-022-32092-8","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T14:19:06Z","timestamp":1658931546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["T cell receptor \u03b2-chain-targeting chimeric antigen receptor T cells against T cell malignancies"],"prefix":"10.1038","volume":"13","author":[{"given":"Fanlin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6617","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-8206","authenticated-orcid":false,"given":"Xuanming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"32092_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver, L. & Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. Cancer 16, 494\u2013507 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"32092_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541\u20131552 (2015).","journal-title":"N. Engl. J. Med."},{"key":"32092_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2019.00126","volume":"9","author":"LD Scherer","year":"2019","unstructured":"Scherer, L. D., Brenner, M. K. & Mamonkin, M. Chimeric antigen receptors for T-cell malignancies. Front Oncol. 9, 126 (2019).","journal-title":"Front Oncol."},{"key":"32092_CR4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","volume":"118","author":"BL Asselin","year":"2011","unstructured":"Asselin, B. L. et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children\u2019s Oncology Group (POG 9404). Blood 118, 874\u2013883 (2011).","journal-title":"Blood"},{"key":"32092_CR5","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","volume":"36","author":"SS Winter","year":"2018","unstructured":"Winter, S. S. et al. Improved survival for children and young adults with T-Lineage acute lymphoblastic leukemia: results from the children\u2019s oncology group AALL0434 Methotrexate Randomization. J. Clin. Oncol. 36, 2926\u20132934 (2018).","journal-title":"J. Clin. Oncol."},{"key":"32092_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","volume":"132","author":"N Schmitz","year":"2018","unstructured":"Schmitz, N., Lenz, G. & Stelljes, M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood 132, 245\u2013253 (2018).","journal-title":"Blood"},{"key":"32092_CR7","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak, V. et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J. Clin. Oncol. 31, 1970\u20131976 (2013).","journal-title":"J. Clin. Oncol."},{"key":"32092_CR8","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya, H. et al. Treatment and survival among 1594 patients with ATL. Blood 126, 2570\u20132577 (2015).","journal-title":"Blood"},{"key":"32092_CR9","first-page":"1043","volume":"60","author":"K Nosaka","year":"2000","unstructured":"Nosaka, K. et al. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res. 60, 1043\u20131048 (2000).","journal-title":"Cancer Res."},{"key":"32092_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/modpathol.2009.196","volume":"23","author":"E Laharanne","year":"2010","unstructured":"Laharanne, E. et al. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod. Pathol. 23, 547\u2013558 (2010).","journal-title":"Mod. Pathol."},{"key":"32092_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood-2016-09-692582","volume":"129","author":"M Sanchez-Martin","year":"2017","unstructured":"Sanchez-Martin, M. & Ferrando, A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood 129, 1124\u20131133 (2017).","journal-title":"Blood"},{"key":"32092_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269\u2013271 (2004).","journal-title":"Science"},{"key":"32092_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood 129, 1113\u20131123 (2017).","journal-title":"Blood"},{"key":"32092_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","volume":"30","author":"S Gill","year":"2016","unstructured":"Gill, S., Maus, M. V. & Porter, D. L. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 30, 157\u2013167 (2016).","journal-title":"Blood Rev."},{"key":"32092_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"32092_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","volume":"12","author":"LC Fleischer","year":"2019","unstructured":"Fleischer, L. C., Spencer, H. T. & Raikar, S. S. Targeting T cell malignancies using CAR-based immunotherapy: Challenges and potential solutions. J. Hematol. Oncol. 12, 141 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"32092_CR17","doi-asserted-by":"publisher","first-page":"e99442","DOI":"10.1172\/jci.insight.99442","volume":"3","author":"J Rasaiyaah","year":"2018","unstructured":"Rasaiyaah, J., Georgiadis, C., Preece, R., Mock, U. & Qasim, W. TCRalphabeta\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 3, e99442 (2018).","journal-title":"JCI Insight"},{"key":"32092_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","volume":"15","author":"G Ma","year":"2019","unstructured":"Ma, G. et al. Targeting T Cell malignancies using CD4CAR T-Cells and implementing a natural safety switch. Stem Cell Rev. Rep. 15, 443\u2013447 (2019).","journal-title":"Stem Cell Rev. Rep."},{"key":"32092_CR19","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png, Y. T. et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 1, 2348\u20132360 (2017).","journal-title":"Blood Adv."},{"key":"32092_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285\u2013296 (2017).","journal-title":"Blood"},{"key":"32092_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"32092_CR22","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J. Clin. Invest 127, 3462\u20133471 (2017).","journal-title":"J. Clin. Invest"},{"key":"32092_CR23","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang, C. M. et al. Autologous T Cells Expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label phase I Trial. Clin. Cancer Res. 23, 1156\u20131166 (2017).","journal-title":"Clin. Cancer Res."},{"key":"32092_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","volume":"132","author":"I Scarfo","year":"2018","unstructured":"Scarfo, I. et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 132, 1495\u20131506 (2018).","journal-title":"Blood"},{"key":"32092_CR25","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia, P. M. et al. Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat. Med. 23, 1416\u20131423 (2017).","journal-title":"Nat. Med."},{"key":"32092_CR26","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D Sanchez-Martinez","year":"2019","unstructured":"Sanchez-Martinez, D. et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood 133, 2291\u20132304 (2019).","journal-title":"Blood"},{"key":"32092_CR27","doi-asserted-by":"publisher","first-page":"e0125373","DOI":"10.1371\/journal.pone.0125373","volume":"10","author":"KS van der Geest","year":"2015","unstructured":"van der Geest, K. S. et al. Quantifying distribution of flow cytometric TCR-Vbeta usage with economic statistics. PLoS One 10, e0125373 (2015).","journal-title":"PLoS One"},{"key":"32092_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1309\/AJCPPT93VZMAREHK","volume":"137","author":"P Tembhare","year":"2012","unstructured":"Tembhare, P. et al. Flow cytometric immunophenotypic assessment of T-cell clonality by vbeta repertoire analysis in fine-needle aspirates and cerebrospinal fluid. Am. J. Clin. Pathol. 137, 220\u2013226 (2012).","journal-title":"Am. J. Clin. Pathol."},{"key":"32092_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.1206954","volume":"333","author":"F Li","year":"2011","unstructured":"Li, F. & Ravetch, J. V. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030\u20131034 (2011).","journal-title":"Science"},{"key":"32092_CR30","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","volume":"31","author":"KH Chen","year":"2017","unstructured":"Chen, K. H. et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia 31, 2151\u20132160 (2017).","journal-title":"Leukemia"},{"key":"32092_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett, T. & Brown, M. P. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharm. 5, 235 (2014).","journal-title":"Front Pharm."},{"key":"32092_CR32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip, B. et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood 124, 1277\u20131287 (2014).","journal-title":"Blood"},{"key":"32092_CR33","doi-asserted-by":"publisher","first-page":"eabd3595","DOI":"10.1126\/scitranslmed.abd3595","volume":"13","author":"S Paul","year":"2021","unstructured":"Paul, S. et al. TCR beta chain-directed bispecific antibodies for the treatment of T cell cancers. Sci. Transl. Med. 13, eabd3595 (2021).","journal-title":"Sci. Transl. Med."},{"key":"32092_CR34","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","volume":"126","author":"CA Ramos","year":"2016","unstructured":"Ramos, C. A. et al. Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J. Clin. Invest. 126, 2588\u20132596 (2016).","journal-title":"J. Clin. Invest."},{"key":"32092_CR35","doi-asserted-by":"publisher","first-page":"12079","DOI":"10.1200\/JCO.2018.36.15_suppl.12079","volume":"36","author":"R Ranganathan","year":"2018","unstructured":"Ranganathan, R. Chimeric antigen receptor T cells targeting the lambda light chain of human immunoglobulin as a viable target for B cell non-Hodgkin lymphoma. J. Clin. Oncol. 36, 12079\u201312079 (2018).","journal-title":"J. Clin. Oncol."},{"key":"32092_CR36","doi-asserted-by":"publisher","first-page":"E6817","DOI":"10.1073\/pnas.1719451115","volume":"115","author":"MJ Smithey","year":"2018","unstructured":"Smithey, M. J. et al. Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection. Proc. Natl. Acad. Sci. USA 115, E6817\u2013E6825 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"32092_CR37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3389\/fimmu.2018.01453","volume":"9","author":"S Sant","year":"2018","unstructured":"Sant, S. et al. Single-Cell Approach to Influenza-Specific CD8(+) T Cell receptor repertoires across different age groups, tissues, and following influenza virus infection. Front. Immunol. 9, 1453 (2018).","journal-title":"Front. Immunol."},{"key":"32092_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nri3328","volume":"12","author":"J Rossjohn","year":"2012","unstructured":"Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L. & Godfrey, D. I. Recognition of CD1d-restricted antigens by natural killer T cells. Nat. Rev. Immunol. 12, 845\u2013857 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"32092_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4866","volume":"5","author":"M Lepore","year":"2014","unstructured":"Lepore, M. et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRbeta repertoire. Nat. Commun. 5, 3866 (2014).","journal-title":"Nat. Commun."},{"key":"32092_CR40","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.4049\/jimmunol.155.3.1544","volume":"155","author":"ML Alegre","year":"1995","unstructured":"Alegre, M. L. et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155, 1544\u20131555 (1995).","journal-title":"J. Immunol."},{"key":"32092_CR41","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.134.6.3994","volume":"134","author":"UD Staerz","year":"1985","unstructured":"Staerz, U. D., Rammensee, H. G., Benedetto, J. D. & Bevan, M. J. Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. J. Immunol. 134, 3994\u20134000 (1985).","journal-title":"J. Immunol."},{"key":"32092_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2016.08.011","volume":"30","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Facilitating T Cell infiltration in tumor microenvironment overcomes resistance to PD-L1 Blockade. Cancer Cell 30, 500 (2016).","journal-title":"Cancer Cell"},{"key":"32092_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-2","volume":"8","author":"KS Seo","year":"2010","unstructured":"Seo, K. S., Park, J. Y., Terman, D. S. & Bohach, G. A. A quantitative real time PCR method to analyze T cell receptor Vbeta subgroup expansion by staphylococcal superantigens. J. Transl. Med. 8, 2 (2010).","journal-title":"J. Transl. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32092-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32092-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32092-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T18:54:23Z","timestamp":1676228063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32092-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32092"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32092-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.W. is an employee of Shanghai Longyao Biotechnology Limited. X.Y. is a consultant of Shanghai Longyao Biotechnology Limited. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4334"}}